DATASHEET: Opto® Memory B Discovery Rabbit Workflow | A4

• Rapid workflow to screen rabbit memory B cells to discover high-value monoclonal antibodies
• Robust activation of rabbit memory B cells using proprietary feeder-free activation media
• Efficient recovery of antigen-specific antibody sequences for downstream characterization and development

DATASHEET: Opto® Memory B Discovery Rabbit Workflow

• Rapid workflow to screen rabbit memory B cells to discover high-value monoclonal antibodies
• Robust activation of rabbit memory B cells using proprietary feeder-free activation media
• Efficient recovery of antigen-specific antibody sequences for downstream characterization and development

DATASHEET: Opto® Plasma B Discovery 4.0 Workflow

• Recovery of 1,000s of hits from over 40,000 individual plasma B cells in a single 4-chip workflow
• Down-selection of lead candidates by functional profiling
• Sequencing and re-expression of >1,000 functionally-characterized antibodies

INFO SHEET: TechAccess Subscriptions

TechAccess Subscriptions provide access to Berkeley Lights’ revolutionary workflows no matter
the size of your lab, your customer base, or budget.

PRESENTATION: Accessing Broad B Cell Diversity to Rapidly Identify High-value Rabbit Monoclonal Antibodies

Opto® B Discovery on the Beacon® optofluidic system enables rapid selection of lead candidates by function-forward screening of B cells in under 1 week. This presentation will introduce Berkeley Lights’ newest antibody discovery workflow, the Opto® Memory B Discovery workflow, and share how customers are using the workflow to screen rabbit memory B cells to rapidly discover rabbit monoclonal antibodies (as presented at Antibody Engineering & Therapeutics 2023).

Webinar: Abveris on Lessons Learned from 2+ Years of Discovering Functional Antibodies on the Beacon

At PEGS EU 2021, Abveris CEO Tracey Mullen shared a few important lessons learned through using the Beacon system for antibody discovery. She discussed how the Berkeley Lights Platform has enabled Abveris to focus on deeply screening their antibodies upstream and only pulling forward the most qualified and functionally relevant antibodies for re-expression.

Webinar: Opto™ Plasma B Discovery 4.0 Fireside Chat

Join members of our Opto Plasma B Discovery 4.0 development team for a panel discussion about our latest antibody discovery workflow.

Customer Spotlight: Amgen on the Berkeley Lights Platform

Philip Tagari, VP Therapeutic Discovery, Amgen, discusses how the Berkeley Lights’ platform has transformed the way Amgen approaches antibody discovery and cell line development.

Brochure: Get to the Clinic First with Best-In-Class Antibody Therapeutics

Find out how Opto™ Plasma B Discovery on the Beacon optofluidic system allows Pharma to succeed against difficult targets and deliver best-in-class antibody therapeutics.

Brochure: Lead Molecules Against Any Target. At Record Pace.

Find out how Opto™ Plasma B Discovery on the Beacon optofluidic system allows CROs to scale their business and rapidly deliver lead molecules even against difficult targets.

Webinar: Rapid Discovery of Functional Antibodies for SARS-CoV-2

Dr. Robert Carnahan, Ph.D., discusses how the Beacon system helped enable the rapid discovery functional antibodies against SARS-CoV-2.

Customer Spotlight: Genovac on Antibody Discovery

Find out how Genovac is delivering 10-fold more lead candidates against difficult targets.

Webinar: Looking to the Future: What’s next in Antibody Therapeutics

At the 2021 AE&T EU conference, Tracey Mullens, CEO of Abveris, and Brian Walters, CEO of Genovac, joined John Proctor, SVP Antibody Therapeutics, for a discussion about the evolving landscape of antibody therapeutics, the technologies they have turned to address today’s complex targets, and how they are preparing for tomorrow’s challenges.

Webinar: Accelerating Discovery and Development of Antibody Therapeutics

Hear from BLI experts Renee Tobias and Anupam Singhal about the unique benefits to leveraging a single platform for both the identification of promising candidates and the production of leading therapeutic molecules.

App Note: Discover Lead Molecules Against Difficult Targets Inaccessible by Hybridoma Methods

Download this application note to learn about how the Opto™ Plasma B Discovery workflow increases hit recovery for difficult membrane-bound targets and provides access to greater sequence diversity when compared to traditional hybridoma methods.

Product Tour: The Opto™ Plasma B Discovery 4.0 Workflow

Antibody expert, Anupam Singhal, PhD, does a 10-minute walkthrough of how the Opto™ Plasma B Discover workflow makes it possible to accelerate lead molecule discovery against difficult targets.

Webinar: Tackle Difficult Targets by Accessing Broad B Cell Diversity

Watch our presentation at AE&T Digital Week, hosted with Genovac, to hear how the Beacon system is making it possible to find 10 times more lead candidates than hybridoma in just days.

Webinar: A Beacon for Rapid Antibody Discovery against Difficult Targets

Panelists from Genovac, will present case studies of how they have leveraged their core genetic immunization technology and the Beacon optofluidic system to rapidly discover antibodies against challenging targets, such as GPCRs, from a variety of different animal species.